C2i Genomics

Curated by Signal

Provider of liquid biopsy for post cancer surgery monitoring

Life Sciences Technologyc2i-genomics.com

Overview

Provider of liquid biopsy for post-cancer surgery monitoring. It provides a tool for cancer tumor monitoring. It identifies changes in genetic patterns across the entire tumor. Based on advanced bioinformatics and AI, it compares thousands of data points obtained from periodic liquid biopsy blood tests of a patient to sequenced tumor tissue and whole-genome analysis.

Key facts

Founded: 2019
Headquarters: New York City, United States
Stage: Sign up to view
Industry: Life Sciences Technology

Business model

3 products and services: Sign up to view

Contact

Primary office: Sign up to view
Email: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

HairDAO
Decentralized research and development network to develop hair loss treatments
Life Sciences TechnologyUnited States
Healid
Blockchain based-AI enabled platform to provide gene therapies
Life Sciences TechnologyBoise, United States
Kardiolytics
Provider of AI-based image processing solution for coronary artery atherosclerotic stenosis
Life Sciences TechnologyChicago, United States

About C2i Genomics

What does C2i Genomics do?

Provider of liquid biopsy for post-cancer surgery monitoring.

Where is C2i Genomics headquartered?

C2i Genomics is headquartered in New York City, United States.

When was C2i Genomics founded?

C2i Genomics was founded in 2019.

Which sector is C2i Genomics in?

C2i Genomics operates in Life Sciences Technology.

Who are C2i Genomics's competitors?

Companies similar to C2i Genomics include HairDAO, Healid, and Kardiolytics.